Corbus Pharmaceuticals Azioni (NASDAQ: CRBP)

Ultime notizie per Corbus Pharmaceuticals (NASDAQ:CRBP) Azioni

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals Holdings Inc

News

DXYZ

Destiny Tech100 Reports Q3 Net Asset Value Of $5.32 Per Share Of Common Stock, An Increase From $5.15 At The End Of Q2

Maximus Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMS#NYSE">MMS</a>) shares are volatile in extended trading Tuesday after the company announced the cancellation of a <a href="https://www.benzinga.com/pressreleases/24/11/b42201228/u-s-department-of-health-and-human-services-centers-for-medicare-and-medicaid-services-notify-maxi">contact center operations contract</a>.
What Happened: After the market close on Tuesday, Maximus said it received notification from the U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services (CMS) that the federal agency has canceled the Contact Center Operations (CCO) 1-800-MEDICARE and Federal Marketplace solicitation.
The company said the contract covered the same scope of work Maximus currently performs under separate contracts through option periods available until 2031.
&#8220;Maximus employees have consistently demonstrated their ability to successfully manage this critical program providing essential support to more than 75 million eligible Americans who rely on Medicare and the Federal Marketplace,&#8221; said Bruce Caswell, president and CEO of Maximus.
&#8220;We appreciate the opportunity to continue supporting HHS and CMS in their vital missions and look forward to delivering innovative, high-quality, and reliable solutions that benefit the American public.&#8221;
Maximus helps improve the delivery of public services&nbsp;as a strategic partner to governments around the world.
MMS Price Action: Maximus shares were volatile at the start of the after-hours session, but were trading approximately flat by the time of publication Tuesday at $73, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42202858/workday-stock-slides-after-q3-results-beat-expectations-fy-subscription-revenue-guidance-revised-lower">Workday Stock Slides After Q3 Results Beat Expectations, FY Subscription Revenue Guidance Revised Lower</a></li>
</ul>
Photo: Shutterstock.

Government

Health Care

After-Hours Center

Movers

Maximus Stock Bounces Around After Hours Tuesday: What's Going On?

Kentucky took a significant step in its medical cannabis program on Monday, awarding the first 36 dispensary licenses through a randomized lottery system. Governor Andy Beshear announced the winners, emphasizing the program's fairness and focus on providing safe and affordable access to medical cannabis for patients with chronic illnesses like cancer and PTSD.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Regional Allocation And Next Steps</h3>
The licenses were distributed across nine of <a href="https://www.benzinga.com/topic/kentucky-cannabis">Kentucky</a>'s 11 designated regions, ensuring geographic spread and reducing travel times for patients. Each region received four licenses, with businesses selected using a random number generator. Winners have 15 days to pay a $30,000 licensing fee or forfeit their license. Additional lotteries for the Lexington and Louisville metropolitan areas will occur on December 16.
Read Also: <a href="https://www.benzinga.com/general/health-care/24/11/41843261/kentucky-gov-beshear-the-jury-is-no-longer-out-kentuckians-want-medical-cannabis">Kentucky Gov. Beshear: &#8216;The Jury Is No Longer Out,&#8217; Kentuckians Want Medical Cannabis</a>
<h3 class="wp-block-heading">Application Surge And Market Stability</h3>
The Kentucky Office of Medical Cannabis received nearly 5,000 applications, with 4,075 specifically for dispensaries. This overwhelming interest reflects the market&#8217;s potential. Executive director Sam Flynn highlighted efforts to avoid over saturation, drawing lessons from Kentucky's hemp industry collapse.
Beshear reiterated the program&#8217;s goal of <a href="https://www.lpm.org/news/2024-11-25/beshear-announces-first-ky-cannabis-dispensary-license-winners-defends-lottery-process">starting small to ensure market stability</a>, with room to expand as demand grows.
<h3 class="wp-block-heading">Concerns About Out-Of-State Influence</h3>
Criticism has emerged over potential out-of-state dominance in the licensing process. Companies linked to multiple winning applications, have raised questions about fairness. Beshear defended the process, noting that each winning business must incorporate and operate within <a href="https://www.benzinga.com/topic/kentucky-cannabis">Kentucky</a>.
Medical cannabis certification for qualifying patients begins December 1, along with an online directory of licensed practitioners. While there is no set timeline for dispensary openings, Beshear assured that businesses have strong incentives to launch quickly, aiming to provide in-state access by January 1, 2025.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/10/41608654/kentucky-and-delaware-held-cannabis-licensing-lotteries-ushering-in-new-regulated-markets">Kentucky And Delaware Held Cannabis Licensing Lotteries, Ushering In New Regulated Markets</a>

Cannabis

Regulations

Legal

Markets

Kentucky Awards First Medical Cannabis Dispensary Licenses

The Company said it is well-positioned to capitalize on the increasing demand for its healthcare solutions and to continue driving value for stakeholders.

Guidance

SYRA

Syra Health Plans To Present At NobleCon20; Says Its Financial Outlook Is Robust, With Strong Revenue Growth And An Expanding Market Presence

Berlin&#8217;s Senator for Justice Felor Badenberg recently criticized Germany's cannabis law. According to Badenberg, contrary to the objectives of the law, legalization actually made the fight against the black market and organized crime more difficult, <a target="_blank" href="https://www.zeit.de/news/2024-11/26/berliner-justizsenatorin-cannabis-gesetz-aufheben" rel="noreferrer noopener">writes</a> Zeit online, according to translation.
"What was touted by the federal government as a milestone in drug policy has proven in practice to be a serious mistake that will cause long-term damage to our country," the CDU politician told the German Press Agency. "It has to be repealed."
On Thursday, Nov. 28th, a conference of justice ministers of the federal states will be held and experiences with the cannabis law will be discussed.
Partial cannabis legalization <a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/04/38023610/heres-what-you-need-to-know-about-weed-legalization-in-germany-that-just-took-effect" rel="noreferrer noopener">took effect in Germany on April 1</a>, making it the third country in the European Union to legalize adult-use cannabis after <a target="_blank" href="https://www.benzinga.com/markets/cannabis/21/12/24601584/maltas-parliament-says-yes-to-cannabis-legalization-becoming-first-in-europe-to-legalize-weed" rel="noreferrer noopener">Malta and</a> <a target="_blank" href="https://www.benzinga.com/markets/cannabis/23/06/33063370/another-eu-country-legalizes-weed-top-gov-official-calls-cannabis-criminalization-a-failure" rel="noreferrer noopener">Luxembourg</a>. Under this first pillar of cannabis legalization, adults over 18 can legally possess up to 25 grams of dried cannabis flower and cultivate up to three marijuana plants at home. One of the biggest breakthroughs under the law is that medical cannabis is essentially <a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/07/39830117/medical-marijuana-regulated-as-ibuprofen-is-one-of-the-biggest-breakthroughs-of-germanys-cannabi" rel="noreferrer noopener">regulated like ibuprofen.</a>
However, Berlin's proposed resolution argues that the law has caused troubles in effort to deal with the illegal market and organized criminal activities, especially in the commercial trade in cannabis products. The issues lies in the fact that the law change disabled telephone surveillance, online searches in its usual extent. This means that not all the evidence are allowed to be used in criminal proceedings.&nbsp;&nbsp;
Read Also: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41885393/germanys-govt-coalition-crisis-is-cannabis-reform-at-risk" rel="noreferrer noopener">Germany&#8217;s Govt. Coalition Crisis, Is Cannabis Reform At Risk?</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a target="_blank" href="https://newsletteremail.benzinga.com/subscribe" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Drug Dealers As Beneficiaries Of The Law</h2>
One specific case that <a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/09/40697724/weed-smuggler-among-few-freed-under-germanys-new-cannabis-law" rel="noreferrer noopener">recently made headlines</a>, involves a 36-year-old man who smuggled 450 kilograms (992.08 lbs) of cannabis into Germany, estimated to be worth 1.9 million euros ($2.1 million). The controversy arises from the new law, which doesn&#8217;t consider cannabis-related crimes as serious crimes and therefore the prosecutors can&#8217;t use encrypted chats from the provider Encrochat as evidence. The man was released, prompting Baden-Württemberg's Minister of Justice, Marion Gentges (CDU), to say, "Drug dealers are beneficiaries of this law.&#8221;
The case was before the Mannheim Regional Court, but the court's judgment is not yet legally binding, writes the outlet. However it is raising questions among the judiciary nationwide, and cannabis opponents are using it as an argument against the reform.
The German government is working on the second pillar of its cannabis legalization law –setting up municipal five-year pilot programs for state-controlled marijuana to be sold in licensed shops. Moreover, it was recently confirmed that <a href="https://www.benzinga.com/markets/cannabis/24/10/41662047/frankfurt-and-hannover-prepare-for-cannabis-sales-study-amid-health-alarms-over-black-market-con" target="_blank" rel="noreferrer noopener">recreational cannabis sales will launch in Hannover and Frankfurt</a> next year under a pilot program set to last five years.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/24/11/42126680/german-cannabis-20-tons-10m-grams-and-thats-only-0-3-of-the-market-whats-missing" target="_blank" rel="noreferrer noopener">German Cannabis: 20 Tons, 10M Grams &#8211; And That&#8217;s Only 0.3% Of The Market, What&#8217;s Missing?</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/42069381/european-leaders-meet-in-berlin-to-discuss-cannabis-policies" target="_blank" rel="noreferrer noopener">European Leaders Meet In Berlin To Discuss Cannabis Policies</a></li>
</ul>
Photo: Courtesy of Plateresca via Shutterstock

Eurozone

Berlin's Justice Senator Says Cannabis Law Benefits Mafia-Like Structures And It Should Be Repealed

fter the closing of the Transaction, Gran Tierra would retain 50 percent working interest in the Assets.&nbsp;

Asset Sales

Gran Tierra Energy Enters Agreement, Under Which Logan Energy Would Acquire 50% And Operatorship Of Portion Of Simonette Montney Assets For C$52M In Cash

Gran Tierra Energy Says Milestone Achieved In Ecuador With Seventh Successful Oil Discovery Further Confirming Significant Potential Of  Arawana / Zabaleta Field Area

The November 20, 2024 letter was sent as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the three month period ended September 30, 2024.
Gundumogula will continue to serve as a director and chairman of the Company's Board.
On November 21, 2024, the Board appointed Jesus Portillo as CEO and a member of the Board, effective as of November 25, 2024. Portillo will retain his current duties and responsibilities as Chief Financial Officer of the Company.

Management

MOND

Mondee Holdings Gets Nasdaq Non-Compliance Letter; Says Prasad Gundumogula Informed Board On Taking Leave Of Absence As CEO, Effective As Of November 25; Jesus Portillo Named As CEO

The Company regrets the continued delays in its quarterly filings, which have been impacted by a confluence of significant events and transactions completed in 2024.&nbsp;
The Company is working diligently to file the Quarterly Reports for both the second and third quarters as promptly as practical, and expects to return to a normal filing cadence in 2025.

RILY

B. Riley Financial Expects To Return To Normal Filing Cadence In 2025; Reveals Notification Of Additional Delinquency With Nasdaq For Late Filing Of Form 10-Q For Period Ended September 30, 2024

HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) reported its fourth-quarter results after Tuesday's closing bell. Here's a look at the key figures <a href="https://www.benzinga.com/pressreleases/24/11/g42201260/hp-inc-reports-fiscal-2024-full-year-and-fourth-quarter-results">from the quarter.&nbsp;</a>
The Details:&nbsp;HP reported quarterly earnings of 93 cents per share, in line with the analyst consensus estimate. Quarterly revenue came in $14.05 billion, which beat the analyst consensus estimate of $13.99 billion and is an increase over sales of $13.82 billion from the same period last year.
<ul>
<li>HP&#8217;s net cash provided by operating activities in the fourth quarter of fiscal 2024 was $1.6 billion. </li>
<li>Accounts receivable ended the quarter at $5.1 billion, up two days quarter over quarter at 33 days.</li>
<li>Inventory ended the quarter at $7.7 billion, down four days quarter over quarter to 63 days.</li>
<li>Accounts payable ended the quarter at $16.9 billion, up seven days quarter over quarter to 138 days.</li>
<li>HP generated $1.5 billion of free cash flow in the fourth quarter.</li>
</ul>
HP also raised its annual dividend by 5%, boosting its quarterly cash dividend from $0.2756 to $0.2894 per share. 
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a>
&#8220;We are pleased with our Q4 performance where we saw revenue growth for the second consecutive quarter, driven by steady progress in Personal Systems and Print,&#8221; said Enrique Lores, HP president and CEO.
&#8220;With momentum heading into FY25, we are well-positioned to capitalize on the commercial opportunity and lead the future of work,&#8221; Lores added. 
Outlook:&nbsp;HP expects first-quarter adjusted earnings of between 70 cents and 76 cents per share, versus the 85 cent estimate, and fiscal 2025 earnings of between $3.45 and $3.75 per share, versus the $3.60 estimate. 
HPQ Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, HP shares are down 7.93% after-hours at $36 at the time of publication Tuesday.&nbsp;
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42203124/ambarella-stock-soars-in-after-hours-trading-tuesday-whats-going-on">Ambarella Stock Soars In After-Hours Trading Tuesday: What&#8217;s Going On?</a></li>
</ul>
Photo: Shutterstock

Earnings

Tech

HP Stock Drops After Q4 Results, Weak Forward Guidance: Details

SANW

S&W Seed Expects High End Of Range To Be At Adjusted EBITDA Breakeven For The Rest Of FY25

Ambarella Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) shares are soaring in Tuesday&#8217;s after-hours session on the heels of the company&#8217;s third-quarter financial results. Here&#8217;s a look at the key <a href="https://www.benzinga.com/pressreleases/24/11/g42200722/ambarella-inc-announces-third-quarter-fiscal-year-2025-financial-results">highlights from the quarter</a>.
What Happened: Ambarella reported third-quarter revenue of $82.65 million, beating analyst estimates of $79.03 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported third-quarter adjusted earnings of 11 cents per share, beating estimates of four cents per share.
&#8220;Company-specific factors are more than offsetting broad market weakness, and we are reporting 30% sequential revenue growth in fiscal Q3, above the high-end of our guidance range, with strength led again by our customers&#8217; new products, especially those incorporating our higher priced AI inference processors,&#8221; said Fermi Wang, president and CEO of Ambarella.
&#8220;Edge AI revenue represented about&nbsp;70%&nbsp;of our total revenue, establishing a new record level, and this momentum is expected to enable growth in both our IoT and Auto markets in F2025 and F2026.&#8221;
Ambarella ended the quarter with $226.5 million in cash, cash equivalents and marketable debt securities, up from $222.3 million at the end of the prior year&#8217;s quarter.
See Also: <a href="https://www.benzinga.com/news/earnings/24/11/42201885/dell-technologies-shares-drop-after-q3-revenue-misses-estimates-details">Dell Technologies Shares Drop After Q3 Revenue Misses Estimates: Details</a>
What&#8217;s Next: Ambarella expects fourth-quarter revenue to be between $76 million and $80 million. Fourth-quarter gross margin is expected to be between 61.5% and 63%, and operating expenses are expected to range between $49 million to $52 million.
&#8220;With the anticipated revenue growth, we intend to drive positive operating leverage and build upon our 15 consecutive fiscal years of positive free-cash-flow,&#8221; Ambarella&#8217;s CEO added.
AMBA Price Action: Ambarella shares were up 22.42% in extended trading at $83.75 at the time of publication Tuesday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

AMBA

Ambarella Stock Soars In After-Hours Trading Tuesday: What's Going On?

S&W Files Q1 2025 10-Q; Says Financial Results Filed Are In Line With Preliminary Financial Results Previously Released

The parties anticipate closing the transaction on December 2, 2024. Upon completion of the transaction, New TechTarget's shares of common stock are expected trade on Nasdaq under the stock ticker symbol "TTGT".
 &nbsp;

TTGT

TechTarget Shareholders Approve Previously Announced Transaction For Combination With Informa Tech's Digital Businesses

A scathing Senate report released on Tuesday has criticized major U.S. airlines for profiting billions from seat selection fees, raising questions about transparency <a href="https://www.benzinga.com/topic/airlines">and consumer fairness. </a>
The Permanent Subcommittee on Investigations revealed that from 2018 to 2023, carriers like American Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>), Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), and United Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) generated $12.4 billion in fees for seat upgrades and preferred placements, <a href="https://www.cnbc.com/2024/11/26/senate-report-slams-airlines-for-raking-in-billions-in-seat-fees.html" target="_blank" rel="noreferrer noopener">CNBC</a> reports.
As travelers face rising costs for options like extra legroom or aisle seats, the report highlighted how these fees, initially marketed as optional, have become a significant revenue stream. CNBC reports that United alone earned $1.3 billion from seating fees last year—outpacing its checked bag-fee revenue for the first time.
Budget carriers like Spirit Airlines (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SAVEQ#OTC">SAVEQ</a>) and Frontier Airlines also came under fire. They incentivize gate agents to enforce bag size policies, sometimes at the expense of passenger experience.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42198763/fed-minutes-reveal-confidence-in-inflation-reduction-yet-flag-divergent-views-on-interest-rate-path-ahead">Fed Minutes Reveal &#8216;Confidence&#8217; In Inflation Reduction, Yet Flag Divergent Views On Interest Rate Path Ahead</a>
Airlines for America, the industry's trade group, defended the fees, stating the competitive landscape allows passengers to pay for what they value. However, consumer advocates argue these practices burden travelers while masking true ticket costs, according to CNBC.
Budget airlines have faced additional scrutiny. Spirit Airlines awarded its CEO a $3.8 million retention bonus just days before filing for Chapter 11 bankruptcy. This financial maneuver came as the company sought to restructure debt while continuing operations <a href="https://www.benzinga.com/general/travel/24/11/42127269/spirit-airlines-ceo-gets-3-8-million-bonus-1-week-before-company-files-bankruptcy">under bankruptcy protection.</a>
Sen. Richard Blumenthal (D-CT), chair of the subcommittee, announced that airline executives will testify at a Dec. 4 hearing titled "The Sky's the Limit—New Revelations About Airline Fees."
The Biden administration passed various <a href="https://www.transportation.gov/briefing-room/biden-harris-administration-announces-final-rule-requiring-automatic-refunds-airline">protections</a> for airline consumers (i.e., automatic refunds after canceled flights).
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42198583/will-trump-lead-us-into-trade-war-with-mexico-president-claudia-sheinbaum-rebukes-threats">Will Trump Lead US Into Trade War With Mexico? President Claudia Sheinbaum Rebukes Threats</a></li>
</ul>
Photo: Shutterstock

Travel

SAVEQ

Senate Targets Airlines Over $12.4 Billion Seat Fees Amid Mounting Scrutiny

Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) reported its third-quarter results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/n42200629/workday-announces-fiscal-2025-third-quarter-financial-results">details from the report. </a>
The Details: Workday reported quarterly earnings of $1.89 per share, which beat the analyst consensus estimate of $1.76. Quarterly revenue came in at $2.16 billion which beat the consensus estimate of $2.13 billion and is an increase over sales of $1.87 billion from the same period last year.
<ul>
<li>Subscription revenues were $1.959 billion, up 15.8% year-over-year.</li>
<li>The 12-month subscription revenue backlog was $6.98 billion, up 15.3% from the same period last year.</li>
<li>Total subscription revenue backlog was $22.19 billion, increasing 20.3% year-over-year.</li>
<li>Operating cash flows were $406 million compared to $451 million in the prior year. </li>
<li>Free cash flows were $359 million compared to $391 million in the prior year.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a>
&#8220;Workday&#8217;s solid performance in Q3 reflects the trust our customers place in us across industries, the global momentum around our AI-driven innovations, and the strength of our partner ecosystem,&#8221; said Carl Eschenbach, CEO of Workday. 
&#8220;Organizations are increasingly consolidating on the Workday platform to reduce total cost of ownership, simplify their operations, and to unlock the power of our best-in-class AI solutions. Workday gives them the ultimate advantage — and that positions our business for long-term success,&#8221; Eschenbach added.
Outlook:&nbsp;Workday revised its fiscal 2025 subscription revenue outlook lower from between $7.7 billion and $7.725 billion to $7.703 billion, representing growth of 17%. 
WDAY Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Workday shares are down 10.32% after-hours at $242 at the time of publication Tuesday. 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock

Personal Finance

WDAY

Workday Stock Slides After Q3 Results Beat Expectations, FY Subscription Revenue Guidance Revised Lower

X Financial Reports Q3 EPADS Of $1.27, Sales Of $225.5M, Both Up From Prior Year

3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) announced its Q3 earnings on Tuesday, November 26, 2024 at 04:15 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
3D Sys missed estimated earnings by -33.0%, reporting an EPS of $-0.12 versus an estimate of $-0.09.
Revenue was down $10.85 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
In the previous quarter, the company missed on EPS by $0.1, resulting in a 8.0% drop change in the share price the following day.
Here's a look at 3D Sys's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.04</td>
<td>-0.08</td>
<td>-0.01</td>
<td>-0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.14</td>
<td>-0.17</td>
<td>-0.11</td>
<td>0.01</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>116.45M</td>
<td>107.63M</td>
<td>126.63M</td>
<td>129.97M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>113.25M</td>
<td>102.91M</td>
<td>114.85M</td>
<td>123.79M</td>
</tr>
</tbody>
</table>

To track all earnings releases for 3D Sys <a href="https://www.benzinga.com/quote/DDD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Summary: 3D Sys Q3

Autodesk Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) reported third-quarter financial results after the market close on Tuesday. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/24/11/n42200628/autodesk-inc-announces-fiscal-2025-third-quarter-results">rundown of the report</a>.
<ul>
<li>Q3 Revenue: $1.57 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $1.56 billion</li>
</ul>
<ul>
<li>Q3 Adjusted EPS: $2.17, versus estimates of $2.12</li>
</ul>
Total revenue was up 11% year-over-year. Total billings increased 28% year-over-year to $1.54 billion. Cash flow from operations was $209 million, while free cash flow totaled $199 million in the quarter. The company ended the period with $1.44 billion in cash and cash equivalents. 
&#8220;Autodesk is leading the industry in modernizing its go-to-market motion. These initiatives enable us to build larger and more durable direct relationships with our customers and to serve them more efficiently. We have already seen significant benefits from these optimization initiatives and there&#8217;s more to come in the next phase,&#8221; said&nbsp;Andrew Anagnost, president and CEO of Autodesk.
See Also: <a href="https://www.benzinga.com/24/11/42199235/mrbeasts-game-show-hits-prime-video-on-dec-19-one-week-ahead-of-netflixs-second-season-of-squid-game">Amazon Prime Vs. Netflix: MrBeast Game Show Arrives Dec. 19, &#8216;Squid Game&#8217; Season 2 Drops 1 Week Later</a>
Outlook: Autodesk expects fourth-quarter revenue to be in the range of $1.623 billion to $1.638 billion versus estimates of $1.621 billion. The company sees fourth-quarter earnings of $2.10 to $2.16 per share versus estimates of $2.12 per share. 
Autodesk anticipates full-year revenue of $6.12 billion to $6.13 billion versus estimates of $6.11 billion. The company expects full-year earnings to be between $8.29 and $8.35 per share versus estimates of $8.27 per share. 
Autodesk announced the appointment of Janesh Moorjani&nbsp;as the company&#8217;s CFO, effective Dec. 16. Management will hold a conference call to further discuss the quarter with analysts and investors at 5 p.m. ET.
ADSK Price Action: Autodesk shares were down 8.53% after hours, trading at $290.83 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy of Autodesk.

Offerings

ADSK

Autodesk Stock Slides On Q3 Earnings: Key Details From Quarter

Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) announced its Q3 earnings on Tuesday, November 26, 2024 at 04:01 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Workday beat estimated earnings by 7.000000000000001%, reporting an EPS of $1.89 versus an estimate of $1.76.
Revenue was up $294.00 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
Last quarter the company beat on EPS by $0.1 which was followed by a 12.0% increase in the share price the next day.
Here's a look at Workday's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.65</td>
<td>1.58</td>
<td>1.47</td>
<td>1.41</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.75</td>
<td>1.74</td>
<td>1.57</td>
<td>1.53</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>2.07B</td>
<td>1.97B</td>
<td>1.92B</td>
<td>1.85B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>2.08B</td>
<td>1.99B</td>
<td>1.92B</td>
<td>1.87B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Workday <a href="https://www.benzinga.com/quote/WDAY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Workday Earnings Review: Q3 Summary

Corbus Pharmaceuticals (CRBP) presents new pre-clinical data at Obesity Week 2024 further characterizing CRB-913, its highly peripherally restricte...

Corbus Pharmaceuticals presents new CRB-913 pre-clinical data at Obesity Week

Andres Y. Maldonado, an analyst from H.C. Wainwright, maintained the Buy rating on Corbus Pharmaceuticals (CRBP – Research Report). The associated ...

Corbus Pharmaceuticals' CRB-913: A Promising and Safer Alternative in Obesity Treatment with a Buy Rating

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on CRBP stock, giving a Buy rating yesterday. Graig Suvannavejh has...

Buy Rating for Corbus Pharmaceuticals on Promising CRB-913 Obesity Treatment and Favorable Risk/Reward Scenario

As of September 30, 2024, the Company had $159.4 million in cash, cash equivalents and investments on hand, which is expected to fund operations th...

Corbus Pharmaceuticals expects cash to fund operations through 3Q27

"We continue to make steady and significant progress across our pipeline," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "We expect t...

Corbus Pharmaceuticals reports Q3 EPS ($1.15), consensus (95c)

An update from Corbus Pharmaceuticals ( ($CRBP) ) is now available. Corbus Pharmaceuticals, an oncology and obesity-focused company, reported a net...

Corbus Pharmaceuticals Reports Q3 2024 Financial Results

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

H.C. Wainwright analyst Andres Maldonado lowered the firm's price target on Corbus Pharmaceuticals (CRBP) to $75 from $80 and keeps a Buy rating on...

Corbus Pharmaceuticals price target lowered to $75 from $80 at H.C. Wainwright

In a report released on November 7, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), wit...

Corbus Pharmaceuticals (CRBP) Receives a Buy from RBC Capital

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

ALKS

APLS

CRBP

DERM

ELAB

NKTR

NONOF

RPRX

SNYNF

TKPHF

VKTX

VRCA

VRNA

Press Releases

Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference

Transforming Oncology: Stocks to Watch in the Oncology Sector

Transforming Cancer Therapy Stocks to Watch In The Oncology Sector

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference

ACON

ATNM

OSTX

PBYI

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Corbus Pharmaceuticals

Notizie

Ultime notizie per Corbus Pharmaceuticals (NASDAQ:CRBP) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO